CellCentric

We are delighted to collaborate with the American Cancer Society Cancer Action Network (ACS CAN), gaining insights on needs and preferences, of those people with multiple myeloma. Will West Tomasz Knurowski Andrew Fergus Debbie Haynes Karen Clegg Kris Frese

CellCentric will be at #ASH24, San Diego. Inobrodib is our pioneering first-in-class, oral p300/CBP small molecule inhibitor drug. In Phase II trials to treat multiple myeloma. ASH Abstracts out Nov 5th. Will West Debbie Haynes Andrew Fergus Tomasz Knurowski

CellCentric’s Karen Clegg and Debbie Haynes in Rio for IMS 2024. We are developing an oral first-in-class drug to treat relapsed refractory multiple myeloma. Clear potential after and alongside antibody-based therapies. Novel mechanism of action, targeting transcription factors p300/CBP. In Phase II clinical trials. #MMSM #multiplemyeloma #IMS24

Great to deepen our experience and expertise in multiple myeloma drug development, with Andrew Fergus joining our leadership team as Chief Development Officer. See: https://lnkd.in/ejsJtkEW Andy was previously Executive Director and Global Project Leader at Takeda Oncology. He has been directly involved in bringing forward several life-changing therapies for multiple myeloma, including Velcade©️and Ninlaro©️. CellCentric’s first-in-class oral drug, inobrodib, is in Phase II clinical trials. We are leading the way with this new approach to treating myeloma.

Today we welcome Andrew Fergus as CellCentric’s Chief Development Officer. Andy is a highly experienced multiple myeloma drug development leader. Most recently, he served as Executive Director and Global Project Leader for Takeda Pharmaceuticals' Oncology Therapeutic Area, focused on myeloma. Andy has been directly involved in several life-changing therapies, including the development of VELCADE® and NINLARO®. Andy brings additional depth of expertise to the company as we continue to advance our first-in-class oral p300/CBP inhibitor, inobrodib. Will West Debbie Haynes Tomasz Knurowski Kris Frese Karen Clegg Thea Stanway

Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral drugs with new modes of action, that are easy to take in the community. New financing maintains inobrodib’s momentum to registration studies. RA Capital Mgmt and Pfizer Ventures now join Morningside as shareholders. Further contribution too from the American Cancer Society’s BrightEdge fund. Press release: https://lnkd.in/d9QpfvFz Endpoints coverage: https://lnkd.in/dg4geESK Business Weekly: https://lnkd.in/e4ZsaJkA #multiplemyeloma

We are pioneering a new approach to treat multiple myeloma, with an oral p300/CBP inhibitor drug, inobrodib. Huge progress has been made in treating the disease, particularly with recent antibody-based therapies (BCMA targeting agents, TCEs). But 75% of people diagnosed still die of the condition. Beyond and alongside existing approaches, there is a need for oral agents with novel modes of action. Community based delivery also helps address health inequities, meeting the needs of people who are not suitable or able to access more complex treatments in specialist centres. New financing maintains full momentum to registration studies. RA Capital Management and Pfizer Ventures now join Morningside as shareholders. Further additional contribution too from the American Cancer Society’s impact fund, BrightEdge. Total funding: $60.7m. Great to have Laura Stoppel of RA Capital joining the Board, as well as Irena Melnikova from Pfizer Ventures. Press release: https://lnkd.in/d9QpfvFz Endpoints coverage: https://lnkd.in/dg4geESK. Many thanks Lei Lei Wu Cambridge Business Weekly: https://lnkd.in/e4ZsaJkA Many thanks Tony Quested #multiplemyeloma Will West Debbie Haynes Tomasz Knurowski Karen Clegg Kris Frese Thea Stanway

We are pioneering a new approach to treat multiple myeloma, with an oral p300/CBP inhibitor drug, inobrodib. New financing maintains full momentum to registration studies. RA Capital Management and Pfizer Ventures now join Morningside as shareholders. Further additional contribution too from the American Cancer Society’s impact fund, BrightEdge. Total funding: $60.7m. Press release: https://lnkd.in/d9QpfvFz Endpoints coverage: https://lnkd.in/dg4geESK. Many thanks Lei Lei Wu. Cambridge Business Weekly: https://lnkd.in/e4ZsaJkA Many thanks Tony Quested. Huge progress has been made in treating multiple myeloma, but 75% of people diagnosed still die of the disease. Beyond and alongside antibody-based drugs, there is a need for oral agents with novel modes of action, easy to take in the community. CellCentric’s inobrodib addresses that clear unmet need. The new funding will take the company’s programme through to full Phase III readiness. We welcome Laura Stoppel and Irena Melnikova to the Board. Early support for the company came from the University of Cambridge, Cambridge Enterprise, Providence, Avlar, Nesta UKI2S/Future Planet Capital and Takeda Ventures, Inc. Thank you for making everything happen. #multiplemyeloma Will West Debbie Haynes Tomasz Knurowski Karen Clegg Kris Frese Thea Stanway

Delighted to confirm $35m investment from RA Capital Management, as well as additional support from the American Cancer Society’s impact fund, BrightEdge. They join Pfizer Ventures now shareholders, alongside Morningside. See press release: https://lnkd.in/d9QpfvFz Huge progress has been made in treating multiple myeloma, but 75% of people diagnosed still die of the disease. Beyond and alongside antibody-based drugs, there is a need for oral agents with novel modes of action, easy to take in the community. CellCentric’s inobrodib addresses that clear unmet need. The new funding will take the company’s programme through to full Phase III readiness. We welcome Laura Stoppel and Irena Melnikova to the Board. See Endpoints coverage: https://lnkd.in/dg4geESK #multiplemyeloma Laura Stoppel Irena Melnikova Will West Debbie Haynes Tomasz Knurowski Karen Clegg Thea Stanway

Oral drug regimes, delivered in community settings, have the ability to reach wider sections of society. The FDA continue to take diversity and inclusion seriously. Latest guidance: https://lnkd.in/eT5AhNTP CellCentric is developing a new oral treatment for multiple myeloma. While cell and antibody-based therapies have brought great progress for patients, they can be complex to administer, and not suitable for many. There is a growing need for complementary approaches, able to be administered in community settings. Despite significant gains in recent times, 75% of people diagnosed with multiple myeloma still die of the disease. There remains a real need for continued progress. #multiplemyeloma Will West Debbie Haynes Tomasz Knurowski Kris Frese Karen Clegg